ONCAlert | Upfront Therapy for mRCC
Videos  >  

Evaluating the Role of CAR T Cells in Multiple Myeloma

Gareth Morgan, MD
Published Online:4:16 PM, Fri March 1, 2019

Gareth Morgan, MD, director of Myeloma Research at NYU Langone's Perlmutter Cancer Center, discusses where he sees the field of CAR T cells headed for the treatment of patients with multiple myeloma.

While there are many treatment options available, these patients are still relapsing, Morgan says. The treatments also have many side effects, so cellular therapy could replace many of the current therapies that are available.

Morgan says CAR T cells could lead to long-term survival with limited toxicity. More clinical trials are necessary to see where these drugs will benefit most.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.